Choosing reagents against the enzymes that write and erase chromatin marks: why an ezh2 antibody reports a catalytic subunit whose activity depends on a complex the antibody cannot see, what a setdb1 antibody, a suv39h1 antibody, an ehmt1 antibody, a kdm6a antibody and an lsd1 antibody each report as writers and erasers, how an hdac1 antibody, an hdac2 antibody, an hdac3 antibody and an hdac5 antibody differ in complex membership rather than in sequence, where a brd2 antibody, a brd4 antibody, a brd7 antibody and a brd9 antibody read marks rather than write them, what a dnmt1 antibody, an arid1a antibody, a sirt1 antibody, a sirt3 antibody, a sirt6 antibody, a bmi1 antibody, a yy1 antibody and a tbp antibody add, why an anti-histone h3 antibody, a histone 3 antibody, an h3.3 antibody and a cenpa antibody are the substrate and the variant rather than the enzyme, and what any of it requires of a chromatin protocol

Designing chromatin work

1. Measure the mark to measure the activity. The enzyme level reports capacity. The abundance of the mark it deposits, and its distribution across the genome, report what the enzyme actually did. Both belong in a chromatin figure.
2. Treat the complex as the unit. Catalytic subunits are inactive alone and their targeting depends on partners. Where the claim concerns targeting, immunoprecipitation of the complex is the informative experiment rather than a blot of the subunit.
3. Use histone variants as their own controls. Variant specific reagents have to distinguish sequences that differ by a few residues. Demand the supplier's discrimination data and, where a conclusion depends on it, confirm with an orthogonal method.
4. Normalise chromatin experiments to total histone. Modification levels are reported relative to the histone carrying them, not to a cytoplasmic loading control. Blot the total histone on the same membrane.
5. Validate chromatin immunoprecipitation reagents separately. An antibody that works on a blot may not work in chromatin immunoprecipitation, where the epitope is in cross linked, native chromatin. Application specific validation is required rather than assumed.

Writers, readers, erasers and the substrate

Four classes of reagent appear in this area and answer four questions: which enzymes are present, which marks exist, which proteins are bound to those marks, and what the substrate itself looks like. Confusing them produces claims the data does not support.

State the class in the figure legend. It costs a phrase and makes the logic of the experiment visible.

Chromatin protocols are their own discipline

Cross linking time, sonication, chromatin concentration and antibody amount dominate the outcome of a chromatin immunoprecipitation, and small changes shift results substantially. Reagent quality is necessary and not sufficient.

Fix the protocol, include a positive and a negative locus in every run, and report both. Those two controls make a chromatin result comparable across time.

Common questions

Does more enzyme mean more modification?

Not reliably. Activity depends on complex assembly, targeting and substrate availability. Measuring the mark itself is what reports the outcome, and both measurements together are what support a mechanistic claim.

Can a blot antibody be used for chromatin immunoprecipitation?

Only if it has been validated for it. The epitope in cross linked native chromatin is presented very differently from a denatured band, and many reagents work in one and not the other.

How should modification blots be normalised?

To the total amount of the histone carrying the mark, on the same membrane. Normalising to a cytoplasmic protein confounds the modification with the amount of chromatin loaded.

Browse by service class

• Compare Gene synthesis on advertised prices